2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents.

B Pajak, E Siwiak, M Sołtyka, A Priebe, R Zieliński, I Fokt, M Ziemniak, A Jaśkiewicz, R Borowski, T Domoradzki, W Priebe

Journal: International journal of molecular sciences 2020;21(1):234

PMID: 31905745

Free Full Text on MDPI View on PubMed

Abstract

The ability of 2-deoxy-d-glucose (2-DG) to interfere with d-glucose metabolism demonstrates that nutrient and energy deprivation is an efficient tool to suppress cancer cell growth and survival. Acting as a d-glucose mimic, 2-DG inhibits glycolysis due to formation and intracellular accumulation of 2-deoxy-d-glucose-6-phosphate (2-DG6P), inhibiting the function of hexokinase and glucose-6-phosphate isomerase, and inducing cell death. In addition to glycolysis inhibition, other molecular processes are also affected by 2-DG. Attempts to improve 2-DG's drug-like properties, its role as a potential adjuvant for other chemotherapeutics, and novel 2-DG analogs as promising new anticancer agents are discussed in this review.

Address: Independent Laboratory of Genetic and Molecular Biology, Kaczkowski Military Institute of Hygiene and Epidemiology, Kozielska 4, 01-163 Warsaw, Poland.; Texas Oncology, Division of Gynecologic Oncology, 910 E. Houston Street, Tyler, TX 75702, USA.; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, 1901 East Rd., Houston, TX 77054, USA.; Biological and Chemical Research Centre, Department of Chemistry, University of Warsaw, 02-089 Warsaw, Poland.

DOI: 10.3390/ijms21010234

Link outs

Free resources

Full Text Sources:

MeSH Terms: Cell Death, Combined Modality Therapy, Deoxyglucose, Glioblastoma, Glucose, Glucose-6-Phosphate, Glucose-6-Phosphate Isomerase, Glycolysis, Hexokinase, Humans